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Background: Excision repair cross-complementation group 1
(ERCC1) is a key component of the platinum-DNA repair mecha-
nism. Ki67 is associated with the clinical course of several malig-
nancies. The associations of ERCC1 and Ki67, clinical features and
survival in small cell lung carcinoma (SCLC), typical carcinoid
(TC), atypical carcinoid (AC), and large cell neuroendocrine carci-
noma (LCNEC) were determined.
Materials and Methods: We included a consecutive series of 186
patients with SCLC treated with platinum-based chemotherapy and
surgically treated patients with TC (n  48), AC (n  15) and
LCNEC (n  27). ERCC1 and Ki 67 were measured by immuno-
histochemistry and scored using published criteria.
Results: The expression of ERCC1 was different among the differ-
ent tumor types (p 0.001). For patient with limited disease as well
as extensive disease SCLC, no association of ERCC1 expression
with survival was observed (p  0.59). However, only 10% of
SCLC tumors expressed ERCC1. For TC and AC, ERCC1 positive
patients had better survival than ERCC1 negative patients. ERCC1
had no prognostic impact for LCNEC. A difference of the percent-
age of Ki67 LI was observed for the different tumor types (p 
0.001). The difference between TC and AC was significant (p 
0.02), as was the difference between low grade (TCAC) and high
grade NE (LCNEC  SCLC) (p  0.001). For all included patients,
a correlation between Ki67 and ERCC1 was observed (RSquare 
0.19, p  0.001).
Conclusion: ERCC1 expression in SCLC treated with platinum-
based chemotherapy has no impact on survival. High expression of
ERCC1 in TC might represent a clue to the failure of platinum-based
therapy in these patients. ERCC1 expression has prognostic impact
in lung carcinoids. Ki 67 might be considered as a supplementary
test to the histopatologic classification of NE tumors.
Key Words: Small cell lung cancer, Carcinoids, Large cell neu-
roendocrine carcinoma, ERCC1, Ki67, Survival.
(J Thorac Oncol. 2010;5: 453–459)
Small cell lung carcinoma (SCLC), large cell neuroendo-crine carcinoma (LCNEC), typical carcinoid (TC), and
atypical carcinoid (AC) comprise a group of lung tumors with
neuroendocrine features (NE). Despite common classification,
these NE are very different regarding natural course of the
disease and treatment strategies. Management with platinum-
based chemotherapy for SCLC results in initial response rates of
60 to 90%. This regimen is recommended for all stages of this
disease and has been a standard first-line therapy for SCLC since
the 1980s.1,2 Early recurrence and subsequent resistance to
therapy is the main cause of poor outcome in these patients and
determination of who would benefit from therapy and who
would not, has potential clinical implications.
In contrast, TC is resistant to platinum-based chemo-
therapy and the optimal treatment for patients with N0 and
N1 status is complete surgical resection with preservation of
as much normal lung as possible.3,4 The optimal procedure
for TC with N2 lymph node metastases is debated. For AC
more extensive resections is commonly advocated5 and me-
tastases to N1 as well as N2 nodes have negative impact on
survival.5,6 Whether a subgroup of these patients might ben-
efit from chemotherapy is largely unknown. Resection is
preferred in early stage LCNEC,7 but limited information
exists regarding chemotherapy for more advanced stages.8
The mechanism of action of platinum drugs is the
formation of platinum-DNA adducts, which cause inter- and
intrastrand cross links, especially in highly proliferating cells.
Unless these are repaired, the cell dies through apoptosis.
Nucleotide excision repair (NER) is involved in the repair of
platinum-induced DNA damage.9,10 Excision repair cross-
complementation group 1 (ERCC1) is one of several proteins
involved in NER. It is the rate-limiting protein and has
retrospectively been associated with resistance against plati-
num-based chemotherapy in different cancer types including
non-small cell lung carcinoma (NSCLC),11–15 although other
studies could not confirm this observation.16 Prospective
studies in NSCLC are available with promising results.17,18
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Only few studies have dealt with the impact of ERCC1
in SCLC.19–21 A survival benefit was noted for patients with
limited disease and low amount of ERCC1 in two of the
studies.19,20 However, the number of patients was rather small
in both series (n  77 and n  85, respectively). Information
on the distribution and the prognostic implication of ERCC1
in TC, AC, and LCNEC is lacking.
High proliferation rate is associated with tumor aggres-
siveness in many tumors, including NE.22 This might be the
result from genomic instability, which is the feature of tumors
with low ERCC1 expression. Whether a correlation between
ERCC1 expression and proliferation rate as measured by
Ki67 exist in NE is unknown.
The purpose of this retrospective study was to determine
the distribution of ERCC1 in tumor tissue from a large cohort of
Danish patients with SCLC and in TC, AC, and LCNEC. We
also aimed to evaluate the association between the level of
ERCC1 and overall survival for SCLC treated with platinum-
based chemotherapy, and the prognostic value of ERCC1 in
patients with TC, AC, and LCNEC treated exclusively with
surgery. Finally, we intended to determine the association be-
tween the proliferative status of NE as measured by Ki67, the
ERCC1 status, and survival. To date, this is the largest group of
NE patients investigated for these associations.
PATIENTS AND METHODS
Patients and Tissue Specimens
Consecutive, histologic specimens coded as SCLC (pri-
mary or metastatic) in the SNOMED system (M8041*) in the
period January 1, 2000, to December 20, 2007, were retrieved
from the Pathology System, Department of Pathology, Herlev
University Hospital, Division Gentofte, Denmark.
A total of 238 specimens were retrieved from this
single institution, which cover a population of about 600,000
inhabitants in the Copenhagen area. Most of patients from the
region with pulmonary infiltrate were diagnosed at Gentofte
Hospital. The diagnosis of SCLC in all specimens was con-
firmed by a single experienced pathologist (B.G.S.) before
entering this study.
Sufficient material for immunohistochemical analyses
for Ki67 and/or ERCC1 was available in 220 patients. For
various reasons, 34 of these patients did not receive chemo-
therapy, leaving 186 patients with SCLC eligible for this
study. The clinical information included age, gender, smok-
ing history (smokers, former smokers, or never smokers
[defined as 100 cigarettes over a lifetime] and number of
pack-years), performance status (PS, according to Eastern
Cooperative Oncology Group), serum lactate dehydrogenate
(LDH), (measured as normal, elevated up to two times the
upper limit, or elevated more than two times the upper limit),
and stage of disease limited disease/extensive disease LD/
ED for SCLC,23 and tumor, node, metastasis stage for TC,
AC, and LCNEC24).
All investigated tumor samples with SCLC were collected
for routine histopathological examination before chemotherapy.
The diagnostic material was endoscopic biopsies from the lung
(n  160) or metastatic tumor tissue from the liver (n  24) or
elsewhere (n  2). No cytologic material was included.
All patients with SCLC were treated in a single depart-
ment (Herlev University Hospital, Department of Oncology)
and received at least one course of chemotherapy. The stan-
dard first-line treatment was a triplet consisting of carbopla-
tin, etoposide, and vincristine. Patients diagnosed with LD
were offered concomitant radiotherapy. At the end of treat-
ment, patients with LD were offered prophylactic cranial
irradiation. Second line treatment consists of either the same
triplet as in the first-line treatment or topotecan. Second-line
platinum-based chemotherapy was generally offered to pa-
tients with progression more than 90 days after ending first-
line treatment. Topotecan was generally offered to patients
with progression less than 90 days after ending first-line
treatment. Palliative radiotherapy to chest and brain, bone or
skin metastasis was administered in some patients. As this
study was retrospective, information regarding response was
not evenly reported and was not included in the analyses.
Forty-eight patients with TC, 15 with AC and 27
patients with LCNEC were also included, and the inclusion
criteria for these patients are described elsewhere.25 In short,
information regarding age, gender, presence or absence of an
endobronchial tumor component, stage, surgical treatment, ad-
juvant therapy, and survival was available. All included patients
with TC, AC, or LCNEC were treated by surgery alone.
All material from TC, AC, and LCNEC was from the
primary tumor in the lung. No cytologic material was in-
cluded. The demographic properties of the patients are sum-
marized in Table 1. The follow-up time for patients with
SCLC was from the day the patient started chemotherapy
until the date of death or January 2009 if alive. The follow-up
time for patients with TC, AC, and LCNEC was from the day
of diagnosis until the date of death or January 2009 if alive.
Survival data were obtained from the Danish Civil
Registration System by linkage to a personal identification
number. The study was approved by the Danish Ethics
Committee on Research Involving Human Subjects (H-A-
2008-120) and the Danish Data Protection Agency
(J.nr.2008-41-2780).
Immunohistochemical Analysis
Formalin fixed, paraffin-embedded samples of tumor
were selected for immunohistochemical studies. Tumor tissue
sections 3 m thick were dried for 1 hour at 60°C, deparaf-
finized in Tissue Clear, rehydrated in a graded ethanol series,
and treated with 3% hydrogen peroxide to block endogenous
peroxidase activity. Antigen retrieval was performed by im-
mersing slides in citrate buffer at pH 6 and microwaving at
high power for 30 minutes. Nonimmune serum was used to
block nonspecific binding. Afterward the sections were incu-
bated with primary monoclonal antibodies to ERCC1 (mouse,
clone 8F1, Neomarkers) at a dilution of 1:300 for 60 minutes
and to Ki 67 (mouse, clone MIB 1, DAKO, Glostrup, Denmark)
at a dilution of 1:1000. The antibodies were visualized using the
Dako EnVision system and diaminobenzidine as a chromogen
in an automated immunostainer (DakoCytomation, TechMate
Horizon, Glostrup, Denmark). The sections were counterstained
with hematoxylin. Positive controls included normal tonsil for
ERCC1 and a lymph node for Ki 67. Negative controls had the
antibody replaced by phosphate-buffered saline.
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Evaluation of Immunohistochemical Analysis
ERCC1
The expression of ERCC1 was assessed semiquantita-
tively by estimating the percentage of tumor cells with
positive nuclei and/or cytoplasmic staining on whole tumor
slides, (0  no staining, 0.1  positive staining in 1–9% of
the tumor cells, 0.5  positive staining in 10–49% of the
tumor cells, 1  positive staining in 50% of the tumor
cells). The staining intensity was also evaluated in a semi-
quantitative way representing the average intensity of the
stained tumor cells (0  no staining, 1  weak staining, 2 
moderate staining, 3  strong staining). The proportion and
intensity scores were then multiplied to obtain a total score,
which ranged from 0 to 3 (H score).11 ERCC1 was also
assessed in the non-neoplastic tissue adjacent to the malig-
nant tumor in a dichotomous way (present or not).
Ki67
The expression of Ki67 was assessed by the labeling
index (LI) determined by counting the number of stained
malignant cells, regardless of the intensity, divided by the
total number of malignant cells. For statistical analyses, the
numbers were grouped in 10 groups (0  no positive cells,
1 1% positive cells, 2 2% positive cells, 3 3% positive
cells, 4  4% positive cells, 5  5–20% positive cells, 6 
21–30% positive cells, 7  31–40% positive cells, 8 
41–60% positive cells, 9  60% positive cells).
Ki67 was evaluated in the areas of highest positivity
and, if possible, 400 malignant cells were counted. ERCC1
was evaluated in areas with optimal preservation of the
malignant cells.
The pathologist (B.G.S.) was blinded to all subject
characteristics and survival status.
Statistical Analyses
The statistical analyses were done in JMP version 6.
The groups were compared with chi-square test and Fisher
exact test. The probability of overall survival was calculated
using the Kaplan-Meier method and compared using the
log-rank test. For determination of multiple factors and in-
teractions related to overall survival, proportional hazard
models were fitted. The correlation between ERCC1 and Ki
67 was calculated using Pearson’s correlation.
RESULTS
Survival by PS, LDH, Gender, and Smoking
Status for Patients with SCLC
PS was significantly associated with survival. The median
survival time for patients in PS 0, 1, 2, 3, and 4 was 11.88, 9.96,
6.84, 0.6, 0.84 months, respectively (p 0.001). An association
between survival and LDH was noted, the median survival time
for patients having normal, elevated up to two times the upper
limit or elevated more than 2 times the upper limit was 10.8,
8.16, and 5.64 months, respectively (p  0.0001).
No difference in survival was observed between men
and women (p 0.43) or according to pack-years (p 0.51).
Survival by Stage for All Included Patients
Significant differences were observed in survival of
patients having LD SCLC (median 11.76 month) compared
ED SCLC (median 7.44 month) (p  0.001). The median
survival for patients with TC, AC, and LCNEC was 14.4, 3.1,
and 2 years as reported previously.25
ERCC1 Expression According to Histology
ERCC1 was expressed in 79% of TC, 67% of AC, 19%
of LCNEC, and 10% in SCLC (p  0.001) with a mean H
score of 0.90, 0.71, 0.15, and 0.02 (p 0.001) (Table 2). The
difference between ERCC1 expression in TC and AC was
nonsignificant (p  0.34), whereas difference between
ERCC1 expression in LCNEC and SCLC was significant
(p  0.009). Furthermore, a significant difference between
ERCC1 expression in TC and AC versus LCNEC and SCLC
was observed (p  0.001).
In the majority of the tumors, the staining was located
in the nuclei, and this was true for all positive SCLC speci-
mens (n  17). In 26% of TC samples granular cytoplasmic
staining was seen.
ERCC1 was expressed in the non-neoplastic epithelial
tissue adjacent to the malignant tumor in all tumor types. The
staining was noted in the nuclei and in the cytoplasm without
significant differences between tumor types (data not shown).
TABLE 1. Patients Characteristics
No. of Patients TC AC LCNEC SCLC
Gender (F/M) 31/17 9/6 11/16 87/99
Age, yr
median (range)
55 (15–83) 64 (43–74) 65 (31–79) 68 (47–93)
PS






Normal NA NA NA 84
Normal  2 45
Normal  2 45
Smoking







IA  IB 42 8 15 NA
IIA  IIB 2 2 3 NA
IIIA  IIIB 2 3 7 NA
IV 0 1 0 NA
NA 2 1 2
LD/ED NA NA NA 63/116
TC, typical carcinoid; AC, atypical carcinoid; LCNEC, large cell neuroendocrine
carcinoma; SCLC, small cell carcinoma; NA, not available; LD, limited disease; ED,
extensive disease.
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Survival According to ERCC1 Expression
For SCLC (all received platinum-based chemotherapy),
expression of ERCC1 was low (10% of tumors with any
staining), therefore H score more than 0 was used as cut-off
point to define positivity. Using this definition, the median
survival for patients with ERCC1 negative tumors was 8.4
month (95% confidence interval [CI] 7.43–9.6 month),
whereas the median survival for patients with ERCC1 posi-
tive tumors was 9.6 month (95% CI 2.17–12.81 month) (p 
0.59). For TC, AC, and LCNEC (none of these patients
received chemotherapy) the survival analysis in relation to
ERCC1 expression was hampered by the few cases and few
deaths. However, patients having TC and AC with ERCC1
above the median had longer survival as compared with
patients with ERCC1 below the median (p  0.01 and 0.008,
respectively), whereas no survival difference was noted for
patients with LCNEC (p  0.51) (Fig. 1A–D).
Ki67 Expression According to Histology
In all positive cases, the staining was located to the
nuclei. In 24% of the SCLC biopsies, crush artifacts made
counting impossible.
Mean Ki 67 LI was 1.81 in TC, 4.00 in AC, 25.56 in
LCNEC, and 41.75 in SCLC (p  0.0001). A significant
difference between Ki67 LI in TC and AC (p  0.02),
between LCNEC and SCLC (p  0.0003), and between TC
and AC as compared with LCNEC and SCLC (p  0.001)
was observed.
The LI for Ki67 in TC and AC is shown in Table 3. LI
was less than or equal to 3% in 88 and 57% of tumors,
respectively. In no TC a LI more than 8% was seen.
FIGURE 1. A, B: Survival probability
of TC and AC according to ERCC1
expression. (Blue line  ERCC1
above the median, red line  ERCC1
below the median).C, D: Survival
distribution of LCNEC and SCLC ac-
cording to ERCC1 expression. (Blue
line  ERCC1 above the median, red
line  ERCC1 below the median).














TC 0.90 25/53 10/21 2/4 10/21 47/100
AC 0.71 5/33 4/27 1/7 5/33 15/100
LCNEC 0.15 2/7 1/4 2/7 22/81 27/100
SCLC 0.02 17/10 0 0 159/90 176/100
TC, typical carcinoid; AC, atypical carcinoid; LCNEC, large cell neuroendocrine carcinoma; SCLC, small cell lung carcinoma.
TABLE 3. Ki67 Labeling Index (Number of Positive Stained
Malignant Cells Divided by Total Number of Malignant
Cells) for TC and AC
Ki67 Labeling Index
1% 2% 3% 4% 5–8% >8% n
TC 32 7 3 3 3 0 48
AC 6 1 1 4 0 2 14
TC, typical carcinoid; AC, atypical carcinoid.
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Ki67 Expression and Survival
Ki67 LI was highly associated with survival (p 
0.001). In multivariate analyses (including tumor type, stage,
age, and sex), tumor type and stage were the strongest
prognostic factors (p for both 0.0001). Ki67 labeling was
borderline significant (p  0.08).
No difference in survival was observed between Ki67
LI and LCNEC and SCLC (p  0.57) or between Ki 67 LI
and TC and AC (p  0.08) (borderline significant). In a
multivariate analysis, stage (p  0.001) and tumor type (p 
0.0002) was the strongest predictor for survival. Because of
small number of patients and few deaths in patients with TC
and AC, we were unable to determine the prognostic signif-
icance of Ki 67 LI in these patients.
Correlation Between Ki67 and ERCC1
For all included patients R-square for the correlation
between ERCC1 and Ki67 was 0.19 (p  0.001). However,
within the different tumor types no association between these
markers could be demonstrated.
DISCUSSION
In this study, the ERCC1 expression as measured by
immunohistochemistry (IHC) was not correlated to survival
in patients with SCLC treated by platinum-based chemotherapy.
However, only 10% of patient with SCLC expressed small
amount of ERCC1, and the CI for the median survival was wide.
The expression of ERCC1 in surgically treated patients with TC
and AC was significantly higher than in SCLC.
Only a few small studies of biomarkers in SCLC have
thus far been published, probably because of the difficulty in
obtaining sufficient and adequate tumor material from patients
with SCLC.19–21,26 To our knowledge, this is the largest study in
which ERCC1 was studied in NE tumors, including SCLC.
In a recent report in which ERCC1 was measured by
IHC in 130 biopsies from Japanese patients with SCLC,
ERCC1 was not related to response nor survival.21 The
patient population differed from our cohort in that only 17%
of the included patients were women and 14% were LD. In a
study by Ceppi et al.,20 ERCC1 as measured by reverse-
transcriptase polymerase chain reaction was an independent
prognostic factor for response and survival but only for
patients with LD. The author emphasized that the statistical
power was limited by the small group of patients (45 LD and
40 ED). Using the same method, a recent in vitro study was
unable to demonstrate a correlation between mRNA expres-
sion of ERCC1 and the chemo sensitivity to cisplatin.27
Lee et al. examined the ERCC1 expression by IHC in
77 Japanese patients with SCLC (LD  40, ED  37). In LD
patients, high expression of ERCC1 (demonstrated in five
patients as compared with 35 with low expression) was an
independent prognostic factor for poor overall survival along
with male gender, whereas ERCC1 was not a predictor for
response. They used the same IHC evaluation of ERCC1
expression as in our and other studies.11 However, the dilu-
tion of their ERCC1 antibody was three times higher. Differ-
ences between ethnic groups of patients with NSCLC in
relation to the quality and quantity of gene mutations, includ-
ing EGFR mutation, has been shown.28 Similar ethnic differ-
ences in the ERCC1-related genes may occur in SCLC. A
survival benefit was shown for Japanese patients with SCLC
treated by cisplatin and the topoisomerase I inhibitor irinote-
can as compared with etoposide plus cisplatin (JCOG
95511).29 However, recently a large North American trial
failed to confirm these results.30 An indirect interaction be-
tween ERCC1 and irinotecan activity has been hypothesized,
as it was shown that the presence of platinum-induced DNA
damage could transiently increase irinotecan activity, result-
ing in increased cytotoxicity.31,32 In NSCLC, increased ex-
pression of TDP1 (an enzyme involved in the topoisomesase
I inhibitor pathway) and XPF (involved in NER by forming
a complex with ERCC1) was shown.33 Thus, differences in
DNA repair capacity due to differences in the amount of
cellular ERCC1 might have an impact on the efficacy of
treatment with irinotecan. Although several factors, including
differences in patient selection, demographics, and treatment
regimens may account for different results observed in the
Japanese and the US studies, impaired action of ERCC1 due
to ethnic differences may also be an explanation.
The potential heterogeneity of tumors might results in
different immunohistochemichal expression of biomarkers
between biopsies and complete surgical specimens, and this
issue has been investigated in NSCLC. These studies have
shown that the expression of markers of cell proliferation
(Ki-67) and DNA repair (ERCC1) assessed in biopsy speci-
mens was significantly correlated with that of the correspond-
ing resected tumor.34–37 This observation in combination with
the fact that the histologic appearance of carcinoids, LCNEC
and SCLC are much less heterogeneous than NSCLC, speaks
against ERCC1 being false negative in SCLC in this study.
SCLC is not a candidate for surgical resection for most of the
patients, and for the majority of the tumors, only a small
specimen is available to investigate biologic marker. How-
ever, SCLC often is crushed with crushed nuclei and in such
areas the evaluation of nuclear markers including ERCC1 and
Ki67 may be difficult.
We demonstrated a significantly higher expression of
ERCC1 in TC and AC than in SCLC. This finding suggests
that the highly malignant behavior of SCLC might be related
to the loss of ERCC1 expression. The impaired nuclear
excision repair could increase genomic instability and, in
turn, lead to more biologically aggressive tumors with higher
proliferation rates.38 TC and AC are generally resistant to
chemotherapy, including platinum-based therapy.39 This
might, at least partly, be related to the high expression of
ERCC1 as demonstrated in several studies regarding the
prognostic impact of ERCC1 in NSCLC.11 Interestingly, in
this study, a better survival was shown for ERCC1 positive
patients with TC (p  0.012) and AC (p  0.008) as
compared with negative patients. However, because of low
number of included patients and low number of events these
results should be confirmed in larger studies.
Expression of ERCC1 has hardly ever been investi-
gated in TC and AC and to the best of our knowledge there
has been only one study, presented as an abstract.40 In that
study, 5/40 TC and 1/26 AC expressed ERCC1 by IHC and
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no correlation was found with age, sex, or survival. The
treatment for the included patients was reported as unknown.
In all tumor types, ERCC1 was detectable in the adja-
cent non-neoplastic tumor tissue with no significant differ-
ence among tumor types. These findings are important for
studies determining the influence of ERCC1 on chemother-
apy as measured by mRNA,16 because this method does not
take into account the amount of normal tissue included in the
test material. The demonstrated different subcellular location
of ERCC1 with granular cytoplasmic ERCC1 staining in
normal tissue as well as in some TC, AC, and LCNEC, but
not in SCLC is interesting. The minimal amount of cytoplasm
and the often crushed biopsy material in SCLC may be the
explanation for this. For some antibodies the subcellular
location is of prognostic significance.41 Whether the cytoplas-
mic ERCC1 protein is associated with specific clinical course
as compared with the nuclear staining is unknown. More studies
are needed to see if low amount of ERCC1 in normal tissue
adjacent to malignant tumor and in other organs may reflect
patients who in general have less repair capacity and thus are
more at risk for developing aggressive, malignant disease.
The ERCC1 expression in LCNEC is largely unknown.
Levels for this tumor type were intermediate between the
levels of TC/AC and SCLC indicating that ERCC1 expres-
sion is related to the aggressiveness of the tumor. Interest-
ingly, none of seven patients with LCNEC in stage III had
detectable levels of ERCC1 as compared with the five
LCNEC stages I and II patients showing positive ERCC1
immunostaining in their tumors (data not shown).
Definition and standardization of the optimal method to
analyze the ERCC1 expression is clearly needed to see if
ERCC1 might be a biologic marker for response and survival
in SCLC treated with platinum-based therapy. Furthermore,
whether ERCC1 negative TC, AC, and LCNEC, especially in
cases with N2 or more disseminated disease, might benefit
from platinum-based chemotherapy has to be shown.
The distinction between TC and AC is based on the
number of mitoses and/or the presence/absence of necroses
on hematoxylin and eosin stained slides.42 Counting mitoses
is time consuming and difficult as the distinction between
pyknotic cells and mitoses can be difficult. The presence or
absence of necrosis may also be difficult as the necroses in
AC often are small and punctuated and the distinction be-
tween true coagulative and “incipient” necrosis can be subtle.
Tumor cell kinetics studies have indicated a relation-
ship between high, uncontrolled cell proliferation rates and
tumor aggressiveness in many tumors including NE. Ki 67
nuclear antigen is associated with cell proliferation and is
detectable in cycling (G1, S, G2, and M-phase) cell but is
absent in resting (G0 phase) cell.43,44 In this study, LI was
never more than 8% for TC, whereas this was the case for
14% of AC. The majority (88%) of TC had LI 3 or less as
compared with 57% of AC. Unfortunately, the number of TC
and AC was too small to make any analyses of the relation
among Ki67, tumor size, endobronchial tumor component, N
stage, residual disease, and survival. The proliferative status
in NE as measured by the immunohistochemical staining for
Ki67 seems to be a method to give diagnostic information on
an equal or higher level than the counting of mitoses as
shown previously.45–50 However, the cut-off for the prolifer-
ative cell population that predicts a benign as opposed to a
more malignant outcome is still questioned.46,50 The Ki-67 LI
may be useful to establish indication for chemotherapy for
patients with gastrointestinal neuroendocrine tumors.51 Che-
motherapy is especially effective in tumors with highly pro-
liferating cells and whether such treatment might benefit a
subgroup of TC as well as and AC remains to be solved.
There is increasing evidence that TC and AC are more
closely associated to each other than to LCNEC and SCLC,
which, in turn, are closely related. Beside differences in
clinical characteristics between the two groups, abnormalities
in several genetic markers such as P53, cylin D1/Rb, and
bcl2/bax are seen more often in LCNEC and SCLC as
compared with TC and AC.52,53 Our results for Ki67 and for
ERCC1 expression are in line with these results.
ERCC1 and Ki67 expression were significantly corre-
lated for all included tumors, although this association could
not be confirmed whit in specific tumor groups. We indenti-
fied a subgroup of patients with TC and AC, having Ki LI
above the median combined with ERCC1 below the median
(data not shown). One could speculate whether these patients
might benefit from chemotherapy.
In conclusion, this retrospective study demonstrates
that ERCC1 expression is low in SCLC and is not associated
with survival of patients treated with platinum-based therapy.
However, because the number of positive cases was small,
the confidence limits on the survival were large, and we
cannot exclude that there can be an association with survival.
We demonstrated that ERCC1 expression is of prognostic
value lung carcinoids, although these data should be con-
firmed in larger series. The proliferative index as measured
by Ki67 might be considered for inclusion in the histopaho-
logical definition of NE tumors.
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